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Abstract 
 
Aliskiren is a non-peptide, orally active renin inhibitor with poor absorption and low 
bioavailability (~2.6%). In order to improve the current drug delivery system, a commercially 
available, biodegradable copolymer, poly(lactide-co-glycolide) (PLGA), was employed for a 
nanoparticle (NP) reformulation of aliskiren. An emulsion-diffusion-evaporation technique was 
implemented where aliskiren and PLGA were dissolved in dichloromethane, ethyl acetate, or 
ethyl acetate/acetone. To an aqueous phase containing 0.25% w/v didodecyldimethylammonium 
bromide (DMAB) as stabilizer, the previously prepared organic phase was added drop-wise. 
Following sonication, NP diffusion was expedited with the addition of water, and the organic 
phase was evaporated to form a suspension. Centrifugation was performed at 10,000 rpm, and 
the supernatant was analyzed for drug entrapment efficiency via ultraviolet-visible spectroscopy 
as well as particle morphology with the use of a transmission electron microscope (TEM). 
Having the highest entrapment efficiency (82.68 ± 1.18 %), ethyl acetate was used as the organic 
solvent in further testing, such as examining the effects of variation in DMAB stabilizer 
concentration (0.10, 0.25, 0.50, or 1.00% w/v) and centrifugation speed (10,000 or 12,000 rpm). 
The optimum formulation was ascertained through observing certain NP characteristics, such as 
entrapment efficiency particle size, zeta potential, and polydispersity index (PDI). A NICOMP 
Particle Sizer was used to measure particle size, zeta potential, and PDI. The smallest NP size 
(67.27 ± 0.87 nm) was accomplished with 0.50% w/v DMAB concentration using a 
centrifugation speed of 12,000 rpm, while the highest zeta potential (18.73 ± 0.03 mV) was 
detected with the 1.00% w/v DMAB concentration and a 10,000 rpm centrifugation speed. 
Further, the best entrapment efficiency and PDI (82.68 ± 1.18 % and 0.15 ± 0.03, respectively) 
were accomplished with 0.25% w/v DMAB and centrifugation at 10,000 rpm. The most 
favorable formulation yielding the highest zeta potential (18.73 ± 0.03 mV) was observed when 
DMAB stabilizer was 1.00% w/v and centrifuged at 10,000 rpm. Particle size and entrapment 
efficiency for this formulation were 75.67 ± 0.89 nm and 71.62 ± 0.11 %, respectively.  
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1. Introduction 
 
Worldwide, approximately 25% of people live with hypertension, a risk factor for 
cardiovascular disease; therefore proper treatment of this potentially serious condition is 
paramount [1]. A diagnosis of hypertension is conferred when a patient, exhibiting neither 
diabetes mellitus nor kidney disease, presents with a blood pressure in excess of 140/90 mm Hg. 
Blood pressure is mainly controlled by the renin-angiotensin-aldosterone system (RAAS) 
through angiotensin II which is produced via the angiotensin-converting enzyme (ACE) from 
angiotensin I [2]. Increased blood pressure is correlated with elevated blood levels of angiotensin 
II, a vasoconstrictor which restricts blood flow thereby increasing vascular resistance [3]. The 
rate-limiting step of RAAS is the process by which renin is secreted due to low plasma volume, 
decreased blood flow through the kidneys, or increased sympathetic central nervous system 
activity. When angiotensinogen, the only known renin substrate in plasma, is cleaved by renin, 
an inactive peptide, angiotensin I, is formed [2]. ACE then transforms angiotensin I into the 
active peptide angiotensin II, which interacts with angiotensin II type 1 (AT1) receptors inducing 
vasoconstriction and the release of catecholamines.  
Although ACE inhibitors block the formation of angiotensin II, angiotensin I continues to 
be produced and may still be converted to angiotensin II via other metabolic pathways [4]. 
Angiotensin receptor blockers specifically block the AT1 receptors[2]. While multiple steps may 
be inhibited to prevent angiotensin II formation, the rate-limiting step is ideal for inhibition as 
renin is the first enzyme in the pathway [5]. Because angiotensin receptors are not activated 
when renin is inhibited, the specific metabolic pathway is not affected [2]. Inhibition at this step 
increases the amount of renin in circulation; however, inhibitors, such as aliskiren, block enzyme 
activity. 
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 Aliskiren (Fig. 1) is a non-peptide, orally active renin inhibitor with attractive properties, 
such as low molecular weight, and was discovered using X-ray crystallographic structure 
analysis and molecular modeling [5]. On March 6, 2007, aliskiren became the first of its drug 
class to receive approval from the United States Food and Drug Administration (FDA) as an 
antihypertensive drug which reduces plasma renin activity through high affinity binding and 
specificity via aromatic side chains [3, 6]. The renin active site is able to accommodate seven 
substrate amino acid units with high affinity [7]. When the production of angiotensin I and 
angiotensin II is decreased, plasma renin concentration is increased, yet plasma renin activity 
(PRA) is decreased [6]. The reduction in PRA is beneficial to cardiovascular health through 
reducing cardiovascular risk factors [3]. Studies have shown that aliskiren is effective as either a 
monotherapy or in combination with other antihypertensive drugs such as hydrochlorothiazide 
[4, 6]. Aliskiren has a half-life of approximately 23 to 36 hours making it suitable for once daily 
dosing, typically 150 or 300 mg. Side effects including headache, diarrhea, and dizziness were 
reported in less than 3% of patients [8]. 
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Figure 1. Chemical structure of aliskiren [9]. 
 
 Although aliskiren has many positive attributes in regard to lowering blood pressure, 
such as reaching maximum plasma concentrations within 2 to 4 hours following administration, 
drug bioavailability has been found to be an extremely low (2.6%) with approximately 91% of 
the drug excreted unmetabolized from the body in feces and urine ( > 0.6%) [2, 4, 5, 8]. 
Aliskiren exhibits high aqueous solubility (low lipophilicity) conferring greater resistant to 
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intestinal degradation [4, 6]. Synthetic polymer nanoparticle (NP) formulations are becoming 
prominent in nanomedicine in an attempt to enhance drug delivery systems through improving 
bioavailability, systematic absorption, and/or minimizing effective dosage [10, 11]. Since the 
current average wholesale cost of aliskiren is $70.20 for a 150 mg dose and $88.60 for a 300 mg 
dose, NP formulations could bring about a reduction in cost and become an appealing option for 
patients who suffer from hypertension [12]. 
 NPs, defined by a range of size from 10 nm to 1000 nm, have the potential to modify 
particle size and surface characteristics which may in turn have a significant effect on drug 
pharmacokinetics and pharmacodynamics [13]. Nanoencapsulation can influence drug stability, 
specificity, efficacy, and/or tolerability [14, 15]. Further advantages include improvement of 
intracellular penetration and oral bioavailability along with the option of targeting drug delivery 
to specific tissues and organs. This is attained by either binding the drug to the exterior surface of 
the NPs or by encapsulating the drug internally [16, 17]. Particle size also plays a role in the 
modifiability of a NP such in the obtaining of certain surface properties which affect degradation 
time, elimination processes, and intracellular uptake. When the diameter of NPs are reduced to 
below 100 nm, degradation in the mononuclear phagocytic system (MPS) can be avoided, 
enabling them to stay in the circulatory system thereby increasing the probability of reaching the 
targeted delivery site [18]. Also, if the drug exhibits a hydrophilic surface, the chances of eluding 
the MPS is greatly decreased. If the MPS does not recognize a particle, macrophages will 
quickly attempt to rid the system of the particle [19]. By altering the NP characteristics, this 
important biological defense can be overcome. 
Particle charge is a characteristic which has a significant effect on NP distribution [11, 
20]. Adherence of cationic charged NPs to the negatively charged cell membrane essentially 
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increases cellular uptake. Lastly, particle shape consisting of short spheres with narrow size 
distribution exhibits effective delivery of the drug because as particle length increases, NP 
binding to the drug decreases [10, 17]. This approach is also advantageous because it can reduce 
drug toxicity and side effects associated with a drug due to the ability of targeting specific organs 
and tissues.   
 The FDA-approved, biodegradable, linear copolymer poly (lactide-co-glycolide) (PLGA) 
is favorable for NP formulation for many reasons, including commercial availability, exceptional 
biocompatibility, and low toxicity [11, 21]. Secondly, when this polyester copolymer undergoes 
hydrolysis (Fig. 2), water diffuses into the sample and causes the acidic end groups on each 
monomer to autocatalyze drug release [22, 23]. The mobility of the polymer chains is then 
greater due to a drop in PLGA molecular weight. The monomers are permitted to diffuse and 
water molecules occupy the newly accessible space causing polymer erosion. Degradation of 
PLGA continues releasing the drug through the porous features at a slow rate, and the acidic 
monomers are then consumed via the Krebs cycle with marginal toxicity [15, 22, 24]. 
Degradation time is affected by the ratio of lactic acid and glycolic acid where the optimum 
degradation time is achieved with a 50:50 ratio [23]. Typically, particle size ranges from 50-500 
nm, which allows smaller size diameters to consistently be obtained [17]. With the use of PLGA 
and other biodegradable polymers, particle size, shape, and charge can be manipulated via 
specific synthetic processes. In order to increase bioavailability, a smaller particle size and 
increased surface charge are optimum characteristics. 
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Figure 2. PLGA copolymer undergoing hydrolysis [14, 25-27]. 
 
The current study will employ an emulsion-diffusion-evaporation technique with an 
organic solvent, didodecyldimethylammonium bromide (DMAB) as the stabilizer, and PLGA as the 
synthetic copolymer. Variations in organic solvent, stabilizer concentration, or centrifugation 
speed will be employed and analyzed in order to assess optimum conditions. Following each 
formulation with various solvents, dichloromethane, ethyl acetate, or ethyl acetate/acetone, 
entrapment efficiency and morphology of NPs will be evaluated, while particle size, zeta 
potential, polydispersity index (PDI), and entrapment efficiency for each formulation with 
varying stabilizer concentration (0.10, 0.25, 0.50, or 1.00% w/v) and centrifugation speed 
(10,000 or 12,000 rpm) will also be studied. 
2. Materials and Methods 
2.1 Materials 
 Aliskiren hemifumarate powder was purchased from ChemScene, LLC (Monmouth 
Junction, NJ, USA). Dichloromethane, DMAB, and PLGA (50:50 copolymer compositions; MW 
30,000–60,000 Da) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Acetone, ethyl 
acetate, high-performance liquid chromatography (HPLC) grade water and acetonitrile were 
purchased from Fischer Scientific Laboratory (Fair Lawn, NJ, USA). 
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2.2 Preparation of Nanoparticles 
NP formulations were prepared based on a previously described method using a variety 
of solvents, stabilizer concentrations, or centrifugation speeds [28].  
2.2.1 Effect of Varying Organic Solvents 
 The method of emulsion-diffusion-evaporation was employed with slight alterations for 
NP formulation. In brief, 50 mg of PLGA was completely dissolved in 3 mL of dichloromethane, 
ethyl acetate, or ethyl acetate/acetone. To the organic solvent, 10 mg of aliskiren was added 
under moderate stirring. Simultaneously, 0.25% w/v of DMAB was placed in water (6 mL) and 
allowed to fully dissolve under moderate stirring. While the aqueous phase was under moderate 
stirring, organic phase was added drop-wise. The suspension was sonicated for 5 minutes at 20 
kHz, then the contents were allowed to stir under a hood for 30 to 40 minutes so evaporation of 
ethyl acetate could occur. Upon completion, each solution was centrifuged at 10,000 rpm using a 
Sorval Biofuge Stratos centrifuge equipped with a Heraeus fixed angle rotor (#3335)(Thermo 
Fisher Scientific Inc, Waltham, MA, USA) for 5 minutes. The supernatant was collected to 
measure entrapment efficiency as well as capture transmission electron microscope (TEM) 
images. 
2.2.2 Effect of Varying Stabilizer Concentration and Centrifugation Speed 
 The variations of stabilizer concentrations for DMAB included 0.10, 0.25, 0.50, or 1.00% 
w/v, while the centrifugation speeds were 10,000 or 12,000 rpm. This allowed for detection of 
the optimum centrifugation speed and DMAB concentration in terms of zeta potential, particle 
size, and entrapment efficiency. 
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2.3 Nanoparticle Characteristics 
 Formulations were evaluated based upon various NP criteria, entrapment efficiency, 
particle morphology, size, zeta potential, and PDI.   
2.3.1 Entrapment Efficiency 
 A 1:3 ratio dilution of collected supernatant to HPLC-grade acetonitrile was performed, 
and the corresponding absorbance values were measured employing the same instrumentation. 
These values were employed for the calculation of entrapment efficiency utilizing the following 
equation: Entrapment efficiency (%)  =  (Amount of aliskiren entrapped in NPs/Total amount of 
aliskiren used for formulation) × 100. 
 For all measurements of entrapment efficiency, a calibration curve was constructed using 
solutions of known aliskiren concentrations (10,000-1,000,000 ng/mL) and measuring their 
absorbance values using ultraviolet–visible spectroscopy (Eppendorf Biophotometer, 
Hauppauge, NY, USA) with a wavelength set at 260 nm.  
2.3.2 Particle Morphology 
To assess aliskiren loaded PLGA-NP shape and surface morphology under varied organic 
solvent conditions, TEM (Tecnai Philips Transmission Electron Microscope; FEI, Hillsboro, 
Oregon, USA) was employed. After vortex mixing, 2 µL aliquots of the NP suspensions were 
positioned on a 200 mesh copper grid containing Formvar film (Electron Microscopy Sciences, 
Hatfield, Pennsylvania). Examination was performed at 80 kV once the samples had air dried for 
1 hour. 
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2.3.3 Particle Size, Zeta Potential, and Polydispersity Index  
 A NICOMP Particle Sizer (Particle Sizing Systems, Port Richy, FL, USA) was used to 
evaluate particle size via dynamic light scattering, while zeta potential was approximated under 
an electrical field with a foundation of electrophoretic mobility. PDI, as an indicative of particle 
size distribution, was also measured by NICOMP Particle Sizer. 
2.4 Data Treatment and Statistical Analysis 
 Each experiment was carried out in triplicate, and the resulting data is presented as mean 
± SD. Variation in centrifugation speeds were compared with the use of a Student's t-test, with a 
p-value < 0.05 indicating a significant difference. * indicates a significant difference between 
two groups. 
3. Results and Discussion 
3.1 Effect of Varying Organic Solvents 
 Different organic solvents were examined in order to determine which solvent would 
yield better results in terms of drug entrapment efficiency and particle morphology.  
3.1.1 Entrapment Efficiency 
 For each known concentration of aliskiren formulation, the absorbance value was 
measured in triplicate, and the average value was plotted against the known concentration of 
aliskiren solution. With an R2 value of 0.99716 (Fig. 3), this calibration curve was employed for 
all entrapment efficiency measurements. 
	  11	  	  
 
 
Figure 3. Standard calibration curve for drug entrapment efficiency. 
It was imperative to choose an organic solvent, which could sufficiently dissolve 
hydrophilic aliskiren as well as produce a desired entrapment efficiency for the PLGA-NP 
formulation. The three readily available and cost effective choices were dichloromethane, ethyl 
acetate, and ethyl acetate/acetone due to their high solubility for many compounds. Additionally, 
solvent toxicity was considered, including the high volatility of dichloromethane as well as its 
toxic tendencies in humans; however, since the method of emulsion-diffusion-evaporation is 
inclusive of complete evaporation of the organic phase upon formation of the PLGA-NP, the 
toxicity is not an issue [29]. On the contrary, ethyl acetate and acetone both show lower toxicity 
than dichloromethane; however, each evaporates at a more rapid rate. Thus, when using these 
solvents, the method of preparing PLGA-NPs had to be performed in a timely manner [30, 31]. 
As shown in Table 1, entrapment efficiency was highest (82.68 ± 1.18 %) for PLGA-NPs that 
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rpm centrifugation speed. The higher value for entrapment efficiency is indicative of an 
increased amount of aliskiren encapsulated in the particular PLGA-NP formulation, which is 
preferable. 
 
Table 1. Effect of various organic solvents at 0.25% w/v DMAB and 10,000 rpm on aliskiren 
entrapment efficiency.  
  Dichloromethane Ethyl acetate Ethyl acetate/acetone 
Entrapment efficiency (%)  73.24 82.70 58.64 
  72.45 81.50 58.12 
  72.56 83.85 60.52 
Average 72.75 82.68 59.09 
S.D. 0.43 1.18 1.26 
 
3.1.2 Particle Morphology 
Fig. 4 displays PLGA-NPs (lighter areas of image) with employment of dichloromethane 
as solvent. Although many NPs are present, the poor NP morphology and increased particle size 
makes this formulation unfavorable as drug delivery to target cells would be inhibited due to 
reduced permeability through epithelial barriers in the body [32]. The shapes of the NPs appear 
to have pointed tips as opposed to the preferred spherical shape. Fig. 5 illustrates PLGA-NPs 
using ethyl acetate as solvent, and of the three images, this formulation exhibited the most ideal 
characteristics, which included spherical morphology, decreased particle size, and the highest 
entrapment efficiency. These conditions are less complimentary to the in vivo conditions of the 
vascular and lymphatic systems, therefore decreasing their chance of clearance from the 
circulatory system [33]. The decreased particle size is related to an increased surface area on the 
NPs which allows for more interaction with the solvent [28]. Lastly, Fig. 6 is representative of 
ethyl acetate/acetone as solvent, and it is observed to have similar physical features to the NP in 
Fig. 5. As opposed to Fig. 5, the entrapment efficiency is the least desirable of all three solvents. 
	  13	  	  
The decreased entrapment efficiency with ethyl acetate/acetone and the poor morphology with 
dichloromethane indicate that, of those organic solvents tested, ethyl acetate is the best choice for 
PLGA-NP formulations in regard to spherical shape and increased entrapment. 
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Figure 4. TEM image illustrating morphology of NPs formulated using dichloromethane. 
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Figure 5. TEM image illustrating morphology of NPs formulated using ethyl acetate. 
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Figure 6. TEM image illustrating morphology of NPs formulated using ethyl acetate/acetone. 
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3.2 Effects of Varying Stabilizer Concentration and Centrifugation Speed 
 
 The use of increasing of concentrations of stabilizer along with variation in centrifugation 
speed allows for the optimization of NP formulation. 
3.2.1 Particle Size 
When DMAB stabilizer concentrations and centrifugation speeds were varied, the first 
characteristic analyzed was particle size. Centrifugation speed alteration produced significantly 
different particle sizes for the PLGA-NP formulations containing 0.10, 0.50, and 1.00% 
stabilizer concentrations. The smallest acquired particle size (67.27 ± 0.87 nm) was found with 
the use of 0.50% w/v DMAB stabilizer and a centrifugation speed of 12,000 rpm (Fig. 7). 
Particles that measure less than 100 nm are small enough to permeate sub-mucosal membranes, 
whereas particles greater than 100 nm remain in the epithelial lining and do not reach the target 
delivery site [15]. In turn, cellular uptake is affected since the number of NPs which reach the 
cell are minimized. Even though the 1.00% w/v DMAB stabilizer spun at 10,000 rpm (75.67 ± 
0.89 nm) was the optimum formulation chosen, as opposed to the 0.50% w/v DMAB stabilizer 
with centrifugation speed of 12,000 rpm, the formulation still encompassed PLGA-NPs that were 
less than 100 nm in size. This made for NPs that also had efficient cellular uptake that bypassed 
the MPS.  
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Figure 7. Effect of DMAB concentration at 10,000 or 12,000 rpm on NP particle size. 
 
3.2.2 Zeta Potential 
For zeta potential, variation in centrifugation speed produced a significant change within 
the formulations employing 0.50 and 1.00% stabilizer concentration. When analyzed, the highest 
zeta potential (18.73 ± 0.03 mV) was seen with 1.00% w/v DMAB stabilizer and 10,000 rpm 
centrifugation speed (Fig. 8). Zeta potential directly affects cellular uptake by creating an 
attraction between the positive surface charge of the PLGA-NP and the negative surface charge 
of the cell membrane. It is desirable to have a more positive zeta potential value, around 20 mV, 
so that the NPs may adhere to the negatively charged cell membrane more adequately [17]. 
Higher bioavailability will be achieved if the PLGA-NP is capable of permeating the cell 
membrane and transported to the primary endosomes within the cell [15]. From there, the PLGA-
NPs can be separated, and selected NPs are recycled to the cell exterior in order to maintain a 
required concentration gradient of NPs in the outside medium of the cell. Without this balance, 
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exocytosis of the NPs will be activated. Inside the cell, the remaining encapsulated PLGA-NPs 
migrate to the cytoplasm where controlled release of aliskiren occurs. This characteristic is 
highly considered when choosing an optimum formulation due to its vital role in cellular uptake 
and drug release.  
 
 
 
Figure 8. Effect of DMAB concentration at 10,000 or 12,000 rpm on NP zeta potential. 
 
3.2.3 Polydispersity Index 
When the PDI of a dispersion is less than 0.1, the particles are said to be narrowly 
dispersed in size. On the contrary, a value that extends beyond 0.3 has broadly dispersed particle 
sizes [10]. In this study, the best PDI (0.15 ± 0.03) value was observed when employing 0.25% 
w/v DMAB stabilizer and 10,000 rpm centrifugation speed (Fig. 9). However, the chosen 
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of 0.321 ± 0.01 for PDI. Though not the highest value, the formulation demonstrated sufficient 
consistently dispersed PLGA-NP in the final formulation. A significant change was observed in 
PDI only in the formulation using 0.50% stabilizer concentration. 
 
 
 
 
Figure 9. Effect of DMAB concentration at 10,000 or 12,000 rpm on NP PDI. 
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delivery system to be considered successful, it is essential to have a high loading capacity in 
order to curtail the overall dosage requirement. Drug loading of NPs is accomplished by adding 
the drug of interest, aliskiren, at the time of NP production, which was done in the methods 
described in previous sections [34]. The larger entrapment efficiency value indicated that there 
was a greater amount of aliskiren bound to the NPs per total amount of aliskiren used for NP 
production. Further, the amount of drug bound to the NPs was greatly influenced by the 
copolymer PLGA and the chemical structure of aliskiren [35]. Entrapment efficiency was 
significantly different between centrifugation speed in all formulations using 0.10, 0.25, 0.50 and 
1.00% stabilizer concentration. 
 
 
Figure 10. Effect of DMAB concentration at 10,000 or 12,000 rpm on NP entrapment efficiency. 
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4. Conclusion 
It is conclusive that the optimum formulation for the aliskiren loaded PLGA-NPs 
includes ethyl acetate as the organic solvent, 1.00% DMAB stabilizer, and 10,000 rpm 
centrifugation speed. For all possible alterations, these conditions offered the highest zeta 
potential, reasonable particle size below 100 nm, agreeable entrapment efficiency, and a uniform 
distribution of NPs in the solution. With the reformulation of the aliskiren loaded PLGA-NPs, 
stability and structural improvement may have been achieved to permit distinct advantages over 
aliskiren without PLGA-NP encapsulation. Additionally, the basis formed by this optimum 
polymer synthetic NP formulation of aliskiren could be beneficial for the development of more 
effective oral dosing of aliskiren in terms of pharmacokinetic factors, such as increased 
bioavailability and systematic absorption, due to an enhanced drug delivery system. Further, 
patient compliance may be more favorable due an estimated reduction of cost for the current 
antihypertensive drug. 
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